公开(公告)号：US20230293608A1

公开(公告)日：2023-09-21

申请号：US18156184

申请日：2023-01-18

申请人： Queen Mary University of London

发明人： Yaohe Wang ,  Ming Yuan ,  Jahangir Ahmed ,  Nicholas Robert Lemoine

IPC分类号： A61K35/768 ,  C12N15/86 ,  A61K39/285 ,  A61K38/19 ,  A61K38/20 ,  A61K48/00 ,  C07K14/535 ,  C07K14/54 ,  C12N7/00

CPC分类号： A61K35/768 ,  C12N15/86 ,  A61K39/285 ,  A61K38/193 ,  A61K38/20 ,  A61K38/208 ,  A61K48/0066 ,  C07K14/535 ,  C07K14/54 ,  C07K14/5434 ,  C12N7/00 ,  C12N2710/24132 ,  C12N2710/24121 ,  C12N2710/24143 ,  C12N2710/24162

摘要： The present invention relates to an oncolytic vaccinia virus and virus vectors for use in cancer therapy where in the virus comprises at least three vaccinia virus promoters which are positioned in the same orientation.

公开(公告)号：US11744861B2

公开(公告)日：2023-09-05

申请号：US16493853

申请日：2018-03-13

申请人： Poseida Therapeutics, Inc.

发明人： Eric M. Ostertag ,  Devon Shedlock ,  Julian David Down

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K31/664 ,  A61K31/7076 ,  A61K35/28 ,  A61K38/17 ,  A61K38/19 ,  A61K38/48 ,  A61K38/52 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  C12N5/0783 ,  C12N9/12 ,  C12N9/22 ,  C12N15/11

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K9/0085 ,  A61K31/664 ,  A61K31/7076 ,  A61K35/28 ,  A61K38/177 ,  A61K38/1774 ,  A61K38/193 ,  A61K38/4873 ,  A61K38/52 ,  A61K39/39 ,  A61K39/3955 ,  A61K45/06 ,  C12N5/0636 ,  C12N9/1241 ,  C12N9/22 ,  C12N15/11 ,  C12Y207/07 ,  C12Y304/22062 ,  C12Y502/01008 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2800/80

摘要： Disclosed are methods of eliminating at least on target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell. Exemplary target cells include, but are not limited to, hematopoietic stem cells (HSCs).

公开(公告)号：US20230248769A1

公开(公告)日：2023-08-10

申请号：US18051492

申请日：2022-10-31

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Jooeun Bae ,  Nikhil C. Munshi ,  Kenneth C Anderson

IPC分类号： A61K35/17 ,  A61P35/00 ,  A61K38/19 ,  A61K38/21 ,  A61K39/39 ,  A61K39/395 ,  C07K7/06

CPC分类号： A61K35/17 ,  A61P35/00 ,  A61K38/193 ,  A61K38/212 ,  A61K38/217 ,  A61K39/39 ,  A61K39/3955 ,  C07K7/06 ,  A61K2039/55544

摘要： This disclosure relates to immunogenic peptides that are specific to B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI), and methods of use thereof.

公开(公告)号：US20230241041A1

公开(公告)日：2023-08-03

申请号：US17640315

申请日：2020-09-03

申请人： PHARMA MAR, S.A.

发明人： Ioannis Metaxas ,  Roger Von Moos

IPC分类号： A61K31/4365 ,  A61P35/00 ,  A61K38/19 ,  A61K45/06

CPC分类号： A61K31/4365 ,  A61K38/193 ,  A61K45/06 ,  A61P35/00

摘要： The use of Lurbinectedin in the treatment of malignant mesothelioma is provided.

公开(公告)号：US20230233657A1

公开(公告)日：2023-07-27

申请号：US18298263

申请日：2023-04-10

申请人： IO BIOTECH APS

发明人： Mads Hald ANDERSEN ,  Per Thor STRATEN

IPC分类号： A61K39/00 ,  A61K38/19 ,  A61K38/20 ,  A61K45/06 ,  C12N9/02

CPC分类号： A61K39/001154 ,  A61K38/193 ,  A61K38/2013 ,  A61K45/06 ,  C12N9/0069 ,  C12Y113/11052 ,  A61K2039/5158 ,  A61K2039/55566 ,  A61K2039/572

摘要： The invention relates to the field of prophylaxis and therapy of cancer. Provided is a Indoleamine 2,3-dioxygenase (IDO) or peptide fragments hereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived herefrom or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. The invention also provides that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. The invention further provides the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.

公开(公告)号：US11707408B2

公开(公告)日：2023-07-25

申请号：US13660508

申请日：2012-10-25

申请人： CORNING INCORPORATED

发明人： Steven Edward DeMartino ,  John Stephen Peanasky ,  Robert Anthony Schaut ,  Wendell Porter Weeks

IPC分类号： A61J1/14 ,  A61J1/00 ,  A61K39/395 ,  C03C3/087 ,  C03C3/091 ,  C03C21/00 ,  C03C4/20 ,  A61J1/06 ,  A61K38/17 ,  A61K38/19 ,  A61K38/28 ,  A61K31/403 ,  A61K38/18 ,  C07K16/24

CPC分类号： A61J1/1468 ,  A61J1/00 ,  A61J1/065 ,  A61K31/403 ,  A61K38/17 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/28 ,  A61K39/3955 ,  C03C3/087 ,  C03C3/091 ,  C03C4/20 ,  C03C21/002 ,  C07K16/241 ,  Y02A50/30 ,  Y10T428/131

摘要： The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, HUMIRA® (Adalimumab).

公开(公告)号：US20230226180A1

公开(公告)日：2023-07-20

申请号：US18154581

申请日：2023-01-13

申请人： Genentech, Inc.

发明人： Jane L. GROGAN

IPC分类号： A61K39/395 ,  A61K31/7088 ,  A61K45/06 ,  C07K16/28 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00 ,  A61K38/00 ,  C07K16/30 ,  C12N15/113 ,  C12N15/115

CPC分类号： A61K39/39558 ,  A61K31/7088 ,  A61K45/06 ,  C07K16/2803 ,  A61K38/193 ,  A61K38/20 ,  A61K38/217 ,  A61K47/6803 ,  A61K47/6851 ,  A61P35/00 ,  A61K39/00117 ,  A61K39/001113 ,  A61K39/001124 ,  A61K39/001129 ,  A61K39/001106 ,  A61K39/001128 ,  A61K39/001138 ,  A61K39/001104 ,  A61K39/001119 ,  A61K39/00114 ,  A61K39/001141 ,  A61K39/001166 ,  A61K39/001109 ,  A61K38/00 ,  A61K39/0011 ,  C07K16/30 ,  C12N15/1138 ,  C12N15/115 ,  Y02A50/30 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/545 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14

摘要： The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.

公开(公告)号：US20230201307A1

公开(公告)日：2023-06-29

申请号：US17906599

申请日：2021-03-17

申请人： Drugrecure ApS

发明人： Lars Skriver ,  Alan Watts

IPC分类号： A61K38/19 ,  A61K9/00 ,  A61K47/26 ,  A61K47/42 ,  A61K47/10

CPC分类号： A61K38/193 ,  A61K9/0078 ,  A61K47/26 ,  A61K47/42 ,  A61K47/10

摘要： Provided here is a liquid formulation comprising recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) for inhalation by nebulization.

公开(公告)号：US11684655B2

公开(公告)日：2023-06-27

申请号：US16996635

申请日：2020-08-18

申请人： Spectrum Pharmaceuticals, Inc. ,  Hanmi Pharm Co., Ltd.

发明人： Gajanan Bhat ,  Shanta Chawla ,  Jae Hyuk Choi ,  Eun Jung Kim ,  Yu Yon Kim ,  Gyu Hyan Lee ,  Hyesun Han

IPC分类号： A61K38/19 ,  A61K47/60 ,  C07K16/46

CPC分类号： A61K38/193 ,  A61K47/60 ,  C07K16/46 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/53

摘要： This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

公开(公告)号：US20230181765A2

公开(公告)日：2023-06-15

申请号：US14994913

申请日：2016-01-13

申请人： CureVac SE

发明人： Florian VON DER MÜLBE ,  Ingmar HOERR ,  Steve PASCOLO

IPC分类号： A61K39/145 ,  A61K38/19

CPC分类号： A61K39/145 ,  A61K38/193

摘要： The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.